
Dry eye and Sjögren disease: Esen Akpek, MD, on screening and referral
Sjögren disease is a chronic systemic autoimmune disease, and dry eye is often among its earliest and most persistent manifestations, yet no systemic therapy is approved by the US FDA for the condition. That may change with dazodalibep (Amgen), an investigational CD40 ligand (CD40L) antagonist fusion protein.1 Full results from the
The randomized, double-blind, placebo-controlled trial enrolled 648 adults with moderate-to-severe systemic disease activity, who received dazodalibep 1500 mg every 4 weeks, dazodalibep 3000 mg every 12 weeks or placebo. Both regimens met the primary end point, reducing European Alliance of Associations for Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores compared with placebo at week 48 (differences of 1.8 and 1.4 points, respectively). The every-4-week regimen also improved patient-reported dryness, including on the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI). The trial did not report ocular-specific measures, such as Schirmer testing or ocular surface staining.1
Ophthalmology Times spoke with Esen K. Akpek, MD, director of the Frances and C. Stephen Foster Center for Ocular Immunology and Inflammation and chief of the Division of Ocular Immunology at Duke University School of Medicine, about what the results mean for eye care. In the following Q&A, Akpek discusses how a systemic therapy could change dry eye screening and referral, the clinical findings that should prompt a rheumatology referral and the ocular end points future trials should include.
This Q&A has been lightly edited for length and clarity.
Ophthalmology Times (OT): What would an approved systemic therapy for Sjögren disease change about how ophthalmologists screen for and refer patients with dry eye?
Esen Karamursel Akpek, MD: An approved systemic therapy could meaningfully change the conversation ophthalmologists have with patients presenting with dry eye. It would provide a stronger incentive to look beyond the ocular surface and consider whether an underlying systemic autoimmune disease may be contributing to the patient's symptoms. Ophthalmologists are often among the first specialists to encounter these patients, putting them in an important position to recognize potential Sjögren disease and facilitate appropriate evaluations for diagnosis. Historically, one of the barriers to pursuing a systemic diagnosis has been the lack of specific, effective treatment options. The availability of a systemic therapy would make earlier identification more actionable. Rather than simply managing ocular symptoms, ophthalmologists could help connect patients with multidisciplinary disease management.
It is important, however, not to overinterpret the OASIZ-301 findings. Although the every-4-week dazodalibep regimen improved patient-reported dryness as measured by ESSPRI, these results do not establish an improvement in ocular surface disease specifically. The absence of ocular-specific end points, such as corneal and conjunctival staining, Schirmer testing or validated eye-specific symptom questionnaires, is an important distinction. Ultimately, the most significant development for ophthalmologists may not be evidence that dazodalibep improves dry eye, but rather that the prospect of an effective systemic treatment makes recognizing and referring patients with suspected Sjögren disease much more clinically consequential.
OT: Which clinical findings in a patient with dry eye should prompt a rheumatology referral as systemic options emerge?
Akpek: Every patient presenting with dry eye should undergo a brief systemic screening questionnaire, much as we routinely obtain a detailed medical history and review of systems in patients presenting with uveitis. This should include questions about past medical history, personal and family history of autoimmune disease and associated systemic symptoms. Specifically, patients should be asked about dry mouth, difficulty swallowing dry foods, recurrent dental caries, salivary gland swelling, fatigue, joint pain and other symptoms that could suggest an underlying autoimmune condition.
Importantly, consideration of Sjögren disease should be independent of the severity of the patient's dry eye symptoms. Although patients with Sjögren disease often have more severe tear film abnormalities and ocular surface damage, their subjective symptoms do not necessarily reflect the extent of their disease. This apparent disconnect may be partly attributable to an accompanying neurotrophic component, with altered corneal nerve function potentially reducing symptom perception despite significant ocular surface disease. Reduced Schirmer measurements and substantial corneal fluorescein or conjunctival lissamine green staining should further raise suspicion. A patient may present with objective signs of significant ocular surface disease long before receiving a systemic diagnosis or even recognizing that their other symptoms may be related.
OT: How well do broad patient-reported dryness measures reflect ocular surface disease in Sjögren disease trials, and which ocular end points would be most informative in future studies?
Akpek: Broad patient-reported dryness measures do not adequately capture the burden of ocular disease in patients with Sjögren disease. Most clinical trials of systemic therapies are designed primarily to assess systemic disease manifestations. Even the symptom assessments do not specifically evaluate ocular involvement. For example, the ESSPRI includes only a single dryness question, asking patients to rate their overall dryness on a scale of 0 to 10. This does not distinguish between ocular, oral and other forms of dryness, nor does it adequately capture the functional impact of dry eye. Dry eye is much more than a sensation of ocular dryness. Fluctuating vision, blurred vision, difficulty reading and limitations in performing daily activities can have a profound impact on quality of life and work productivity. Incorporating validated, eye-specific patient-reported outcome measures into future trials is therefore essential.
Equally important is the selection of objective ocular end points. Schirmer testing is frequently included in Sjögren disease trials, but from an ophthalmologist's perspective, tear production is primarily an indicator of lacrimal gland damage related to disease severity and chronicity. Improvement in Schirmer measurements may not necessarily be achievable, even with effective systemic treatment, and may not be the most meaningful measure of therapeutic benefit. Ocular surface staining, particularly corneal fluorescein and conjunctival lissamine green staining, is arguably more relevant when evaluating improvements in ocular surface health. Corneal staining is especially important because corneal epithelial damage can directly affect visual quality, functional vision and vision-related quality of life. These measures should be incorporated alongside eye-specific symptom questionnaires in future clinical trials.
Finally, we should not overlook the broader spectrum of ocular involvement in Sjögren disease. Potentially vision-threatening inflammatory manifestations, including scleritis, uveitis and peripheral ulcerative keratitis, are important ocular manifestations but are not captured in current systemic disease activity measures. Future trials should consider incorporating these manifestations into their assessments, where appropriate.
References
1. Amgen announces positive phase 3 results for dazodalibep in Sjögren’s disease. News release. Amgen. November 11, 2026. Accessed November 18, 2026. https://www.amgen.com/newsroom/press-releases/2026/11/amgen-announces-positive-phase-3-results-for-dazodalibep-in-sjgrens-disease
2. Annual meeting resources. American College of Rheumatology. Accessed November 18, 2026. https://rheumatology.org/annual-meeting-resources/
Related to this article








